Monoclonal antibodies that specifically target the IL‐4Rα inhibiting IL‐4/−13, or which target IL‐5/IL‐5Rα, demonstrate the greatest therapeutic effect in people with severe asthma who are T2 biomarker‐high (FeNO and blood eosinophils for IL‐4/−13, blood eosinophils for anti‐IL‐5).13, 14. Here, IL5 is linked to asthma.